Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics, Inc. (CLDI) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · CLDI · as of Sep 30, 2025
Ownership Breakdown
22
Institutional Holders
▼ 13 vs Q2
$321,694
Total Inst. Value
▼ $334,130 vs Q2
7.37M
Shares Outstanding
freeFloat 74.67%
211,554
13F Shares Held
▼ 2.64M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
CLDI largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
HIGHTOWER ADVISORS, LLC blank checks | 85.0K | 1.73% | 1.73% | $129.13M | Nov 7, 2025 | NEW |
VANGUARD GROUP INC blank checks | 34.7K | 70.77% | 70.77% | $52.79M | Nov 7, 2025 | NEW |
GEODE CAPITAL MANAGEMENT, LLC blank checks | 29.6K | 60.31% | 60.31% | $44.98M | Nov 12, 2025 | NEW |
BELPOINTE ASSET MANAGEMENT LLC blank checks | 20.8K | 42.43% | 42.43% | $31.65M | Nov 3, 2025 | NEW |
WARBERG ASSET MANAGEMENT LLC blank checks | 18.7K | 38.12% | 38.12% | $28.43M | Nov 6, 2025 | NEW |
RS CRUM INC. blank checks | 15.3K | 31.09% | 31.09% | $23.19M | Nov 12, 2025 | NEW |
UBS GROUP AG blank checks | 2.6K | 5.23% | 5.23% | $3.90M | Nov 13, 2025 | NEW |
FINEPOINT CAPITAL LP blank checks | 1.0K | 2.12% | 2.12% | $1.58M | Nov 13, 2025 | NEW |
HIGHBRIDGE CAPITAL MANAGEMENT LLC blank checks | 1.0K | 2.12% | 2.12% | $1.58M | Nov 10, 2025 | NEW |
APOLLO MANAGEMENT HOLDINGS, L.P. blank checks | 1.0K | 2.12% | 2.12% | $1.58M | Nov 14, 2025 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
0
Increased
+0 shares22
New Positions
first time holders1
Decreased
−26.5K shares27
Sold Out
fully exitedNet shares change (top 50)
26.5K
+0 / −26.5K
Net new holders
-6
22 new / 27 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
CLDI insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
15
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Camaisa Allan director | Dec 12, 2025 | Sale | 850 | $1.46 | $1.2K | 77.0K | Form 4 ↗ |
Poma Eric E Chief Executive Officer | Sep 3, 2025 | Award | 10,000 | $1.58 | $15.8K | 10.0K | Form 4 ↗ |
Fernandez Santidrian Antonio Chief Scientific Officer | Sep 3, 2025 | Award | 35,000 | $1.58 | $55.3K | 35.0K | Form 4 ↗ |
Jackson Andrew C. Chief Financial Officer | Sep 3, 2025 | Award | 30,000 | $1.58 | $47.4K | 30.0K | Form 4 ↗ |
Schoeneck James A director | Aug 21, 2025 | Purchase | 75,000 | $2.00 | $150.0K | 76.1K | Form 4 ↗ |
Schoeneck James A director | Aug 21, 2025 | Purchase | 75,000 | $2.00 | $150.0K | 75.0K | Form 4 ↗ |
Poma Eric E Chief Executive Officer | Aug 21, 2025 | Purchase | 25,000 | $2.00 | $50.0K | 25.0K | Form 4 ↗ |
Poma Eric E Chief Executive Officer | Aug 21, 2025 | Purchase | 25,000 | $2.00 | $50.0K | 25.0K | Form 4 ↗ |
Leftwich Scott director | Aug 21, 2025 | Purchase | 125,000 | $2.00 | $250.0K | 130.7K | Form 4 ↗ |
Leftwich Scott director | Aug 21, 2025 | Purchase | 125,000 | $2.00 | $250.0K | 125.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Calidi Biotherapeutics, Inc. (CLDI) is primarily owned by institutional investors, who hold approximately 2.9% of total shares outstanding. Company insiders own approximately 25.33%, while retail and public investors account for the remaining 71.80%.
The largest institutional shareholder of Calidi Biotherapeutics, Inc. is HIGHTOWER ADVISORS, LLC, holding approximately 84,956 shares — equal to 1.73% of outstanding shares — as of September 30, 2025.
A total of 22 institutional investors currently hold CLDI stock, with a combined institutional value of approximately $321,694 as of the most recent 13F filing period.
Frequently asked questions
CLDI ownershipCalidi Biotherapeutics, Inc. (CLDI) is primarily owned by institutional investors, who hold approximately 2.9% of shares. The largest shareholder is HIGHTOWER ADVISORS, LLC with a 1.73% stake. Company insiders hold 25.33%. Data sourced from SEC Form 13F as of September 30, 2025.